Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Axsome Therapeutics Inc

Current price
67.43 USD -0.57 USD (-0.84%)
Last closed 68 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 217 725 952 USD
Yield for 12 month -12.76 %
21.11.2021 - 28.11.2021

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. Address: 22 Cortlandt Street, New York, NY, United States, 10007


WallStreet Target Price

115.45 USD

P/E ratio

Dividend Yield

Current Year

+50 037 106 USD

Last Year

Current Quarter

+57 794 000 USD

Last Quarter

+46 700 000 USD

Current Year

+44 839 511 USD

Last Year

Current Quarter

+51 262 000 USD

Last Quarter

+42 101 000 USD

Key Figures AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -178 810 384 USD
Operating Margin TTM -107.8 %
PE Ratio
Return On Assets TTM -24.14 %
PEG Ratio
Return On Equity TTM -94.56 %
Wall Street Target Price 115.45 USD
Revenue TTM 223 441 104 USD
Book Value 5.7 USD
Revenue Per Share TTM 5.03 USD
Dividend Share
Quarterly Revenue Growth YOY 243.1 %
Dividend Yield
Gross Profit TTM 45 939 511 USD
Earnings Share -4.57 USD
Diluted Eps TTM -4.57 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -90.33 %

Dividend Analytics AXSM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 16.3663
Price Sales TTM 14.4008
Enterprise Value EBITDA -18.006
Price Book MRQ 11.9393

Financials AXSM

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators AXSM

For 52 weeks

53.71 USD 91.29 USD
50 Day MA 64.97 USD
Shares Short Prior Month 7 345 238
200 Day MA 70.29 USD
Short Ratio 10.6
Shares Short 7 642 617
Short Percent 19.45 %